middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
coronaviru
previous
call
novel
human
coronaviru
erasmu
medic
center
hcovemc
viru
discov
first
time
saudi
arabia
zaki
et
al
world
health
organ
confirm
case
human
infect
merscov
countri
sinc
infect
patient
die
feb
howev
saudi
arabia
still
highest
report
merscov
mortal
rate
approxim
case
report
occur
merscov
belong
famili
coronavirida
order
nidoviral
one
recent
report
zoonot
virus
famili
coronavirida
classifi
four
genera
genu
divid
linag
subgroup
merscov
belong
lineagec
coronavirus
although
bat
main
reservoir
coronavirus
dromedari
camel
consid
known
reservoir
merscov
date
addit
merscov
isol
dromedari
camel
rel
close
relat
bat
coronavirus
accord
merscov
transmiss
human
possibl
occur
middl
east
countri
republ
korea
viral
spread
observ
among
healthcar
worker
among
individu
visit
merscovposit
patient
control
outbreak
achiev
local
center
diseas
control
prevent
cdc
immunocompromis
individu
well
patient
comorbid
group
prone
sever
merscov
infect
may
lead
death
infect
patient
mani
case
three
merscov
protein
express
envelop
viru
surfac
spike
protein
membran
glycoprotein
envelop
protein
e
protein
respons
viral
entri
via
attach
fusion
host
cell
membran
merscov
host
cell
receptor
identifi
cluster
differenti
also
known
dipeptidyl
interact
merscov
protein
receptor
facilit
viral
access
host
cell
also
trigger
signal
induc
immunosuppress
infect
patient
enabl
viral
replic
spread
despit
ongo
research
develop
specif
therapi
vaccin
merscov
current
effect
prophylaxi
therapi
merscov
hinder
treatment
control
viral
infect
understand
mechan
immun
respons
merscov
infect
make
develop
effect
vaccin
candid
achiev
especi
vaccin
candid
strong
enhanc
cellular
humor
immun
review
discuss
innat
immun
acquir
immun
respond
merscov
infect
light
uptod
literatur
field
research
moreov
highlight
recent
advanc
field
merscov
vaccin
dendrit
cell
dc
import
contributor
innat
immun
trigger
product
larg
quantiti
cytokin
chemokin
cell
abil
migrat
peripher
tissu
lymphoid
tissu
activ
cell
popul
thu
dc
consid
potenti
target
pathogen
invas
form
bridg
innat
adapt
immun
subsequ
cell
cellmedi
immun
b
cell
humor
immun
arm
adapt
immun
respons
stimul
specif
respons
mechan
immun
respons
trigger
merscov
infect
immun
evas
strategi
yet
fulli
studi
interestingli
merscov
evolv
strategi
manipul
innat
immun
prevent
block
ifn
product
pathway
abil
may
contribut
substanti
high
casefat
rate
merscovinfect
patient
especi
immunocompromis
pattern
recognit
receptor
prr
tolllik
receptor
tlr
retino
acid
induc
genei
rigi
like
receptor
essenti
mediat
innat
immun
respons
viral
recognit
tlr
one
two
differ
adaptor
molecul
myeloid
differenti
primari
respons
receptor
tir
domaincontain
adapterinduc
trif
molecul
activ
mapk
pathway
respons
promot
product
proinflammatori
cytokin
ifn
meanwhil
spike
protein
merscov
trigger
express
neg
regul
tlr
signal
pathway
induct
subsequ
result
express
kinas
irakm
peroxisom
proliferatoractiv
ppar
neg
regul
transcript
factor
induc
express
longterm
persist
neg
regul
impair
clearanc
merscov
infect
therefor
merscov
persist
site
infect
establish
trifdepend
signal
use
pathway
activ
downstream
effector
howev
mice
lack
sever
sarscov
infect
wildtyp
mice
thu
protect
signal
role
might
consid
distinct
featur
pathogenesi
coronavirus
believ
use
special
adjuv
agonist
plu
express
merscov
protein
may
help
improv
immunogen
merscov
infect
initi
activ
interferon
regulatori
factor
ie
bind
ligand
manner
independ
agonist
poli
ic
recent
report
potenti
therapi
mercov
infect
mous
model
administr
poli
ic
type
interferon
express
induc
figur
thu
differ
effector
natur
killer
cell
cell
macrophag
activ
antivir
effect
trigger
known
proinflammatori
cytokin
respons
product
infect
sever
drawback
host
patholog
damag
tissu
contrast
proinflammatori
cytokin
respons
control
viral
dissemin
understand
tlr
signal
pathway
context
merscov
infect
contribut
control
viral
infect
therebi
mitig
risk
spread
gener
ifn
play
import
role
viral
infect
stimul
doublestrand
rna
dsrna
studi
conduct
chu
et
al
demonstr
monocytederiv
dendrit
cell
modc
infect
merscov
exhibit
express
despit
margin
earli
express
howev
anoth
recent
studi
fail
stimul
proinflammatori
innat
respons
fail
produc
type
ifn
vitro
cultur
infect
cell
primari
human
airway
epitheli
cell
modc
infect
merscov
mechan
behind
respons
may
initi
relat
interfer
signal
pathway
usual
respons
induct
proinflammatori
respons
addit
possibl
number
regulatori
cell
induc
site
infect
neg
impact
express
proinflammatori
cytokin
recent
treatment
show
promis
trend
merscovinfect
cell
effect
applic
merscovinfect
cell
greater
sarscovinfect
cell
addit
hart
et
al
studi
differ
ifn
product
two
differ
antivir
drug
name
ribavirin
mycophenol
acid
mpa
merscov
infect
vitro
research
show
potent
inhibitori
effect
merscov
comparison
test
ifn
compar
ribavirin
treatment
mpa
treatment
caus
stronger
inhibit
viral
replic
vitro
mpa
shown
enhanc
ifnstimul
gene
express
suggest
mpa
depend
modul
express
ifnstimul
gene
thu
mpa
might
provid
altern
treatment
merscov
infect
mpa
combin
singl
therapi
might
provid
great
benefit
potent
inhibitor
treatment
merscovinfect
patient
reduc
viral
load
fda
approv
use
mpa
indic
therapi
current
use
merscov
infect
replic
insid
macrophag
subsequ
induc
express
mhci
mhcii
costimulationrel
gene
research
investig
great
impact
merscov
spike
glycoprotein
respons
macrophag
monocyt
cell
via
signal
pathway
shown
merscov
protein
neg
impact
product
proinflammatori
cytokin
contrast
viru
increas
product
antiinflammatori
cytokin
suggest
nichol
et
al
cytokin
releas
alveolar
macrophag
could
substanti
effect
pathogen
sarscov
merscov
infect
stimul
product
type
ifn
infect
cell
lead
releas
chemokin
cytokin
respons
cell
recruit
known
helper
cell
natur
killer
nk
cell
requir
signal
activ
contribut
activ
two
main
arm
immun
respons
help
clear
virus
nk
cell
cell
howev
persist
neg
impact
express
ifn
figur
mahallawi
et
al
found
remark
differ
cytokin
express
profil
merscovinfect
patient
healthi
control
group
context
merscov
infect
product
increas
patient
sera
within
day
postinfect
howev
patient
recov
toler
infect
persist
viral
replic
due
increas
express
level
thu
cytokin
neg
impact
antivir
effect
anoth
studi
report
upregul
express
merscovinfect
patient
compar
healthi
volunt
posit
impact
product
proinflammatori
cytokin
mediat
janu
kinasesign
transduc
activ
transcript
jakstat
pathway
cytokin
product
posit
correl
respons
ie
express
turn
inhibit
type
ii
ifn
express
level
express
cytokin
also
associ
persist
viral
infect
human
immunodefici
viru
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
cell
key
player
requir
immun
viral
infect
cell
facilit
virusspecif
antibodi
product
tdepend
activ
b
cell
howev
cell
cytotox
kill
virusinfect
cell
comparison
celldefici
balbc
mice
mediat
transduct
control
mice
b
celldefici
mice
research
determin
cell
abl
surviv
destroy
virusinfect
cell
infect
lung
report
may
highlight
import
role
cell
b
cell
control
finetun
pathogenesi
outcom
merscov
infect
zhao
et
al
infect
balbc
mice
either
sarscov
merscov
subsequ
mice
challeng
virus
week
later
result
confirm
initi
infect
sarscov
led
signific
decreas
merscov
titer
day
postinfect
thu
crossreact
cell
respons
may
result
decreas
merscov
titer
role
b
cell
respons
context
merscov
infect
studi
activ
cell
antimerscov
antibodi
crucial
clearanc
initi
infect
protect
subsequ
challeng
viru
respect
find
impli
respons
merscov
gener
occur
antibodymedi
immun
anoth
studi
demonstr
mice
vaccin
dna
encod
modifi
sarscov
glycoprotein
develop
protect
immun
result
induct
cell
product
neutral
antibodi
protect
mainli
due
antibodydepend
celldepend
respons
yang
et
al
report
specif
memori
cell
spike
protein
effect
viral
clearanc
even
day
postchalleng
result
confirm
virusspecif
cell
deplet
howev
effect
cell
deplet
time
monitor
differ
interv
henc
antivir
effect
deplet
cell
may
import
later
infect
time
point
lead
persist
viral
infect
promot
viral
surviv
moreov
cours
merscov
infect
viru
invad
immun
system
downregul
mhci
mhcii
antigenpres
cell
apc
subsequ
inhibit
cell
respons
event
may
impair
function
b
cell
cell
via
downregul
receptor
recent
induct
immunosuppress
cours
merscov
infect
promot
apoptosi
cell
identifi
anoth
strategi
manipul
surviv
pathway
host
immun
respons
thought
may
play
signific
role
signal
activ
cell
cours
merscov
infect
cell
isol
human
peripher
blood
pb
tonsil
spleen
lymphoid
organ
could
infect
merscov
sarscov
infect
pattern
might
attribut
low
express
sarscov
receptor
name
angiotensinconvert
enzym
cell
recent
studi
report
helper
cell
suscept
merscov
infect
addit
merscov
induc
cell
apoptosi
activ
intrins
extrins
apoptosi
pathway
interestingli
signific
upregul
express
level
merscovinfect
patient
helper
cell
especi
cell
produc
proinflammatori
cytokin
via
signal
pathway
find
suggest
merscov
infect
promot
induct
cytokin
cytokin
recruit
neutrophil
monocyt
site
infect
inflamm
lead
activ
downstream
cytokin
chemokin
cascad
neutral
antibodi
potent
neutral
viral
infect
block
entri
host
cell
detect
specif
antibodi
merscov
human
serum
consid
one
confirm
diagnos
infect
merscov
crucial
determin
whether
antibodi
potent
arm
adapt
respons
merscov
infect
howev
detect
antimerscov
antibodi
respons
occur
day
infect
antibodi
concentr
increas
time
last
month
longterm
antibodi
respons
depend
sever
infect
antisarscov
antibodi
respons
remain
detect
month
postinfect
begin
gradual
decreas
complet
disappear
year
infect
known
coronavirus
express
surfac
spike
glycoprotein
consid
predomin
antigen
protein
stimul
antibodi
respons
antibodi
might
use
target
spike
protein
block
entri
viru
host
cell
therefor
design
monoclon
antibodi
direct
protein
prefer
protect
contrast
vaccin
prepar
timeconsum
labori
process
date
vaccin
either
sarscov
merscov
avail
market
despit
laboratori
clinic
trial
studi
report
coleman
et
al
prove
mice
vaccin
coronaviru
nanoparticl
technolog
gener
high
level
neutral
antibodi
homolog
virus
antibodi
crossprotect
heterolog
virus
hand
previou
studi
perform
chan
et
al
show
antibodi
recov
serum
convalesc
sar
patient
might
crossreact
merscov
neutral
anoth
studi
suspect
antibodi
may
crossreact
merscov
epitop
recogn
crossreact
antibodi
might
situat
spike
protein
sarscov
least
might
present
receptor
bind
domain
rbd
find
antimerscov
antibodi
kenya
consist
result
report
recent
saudi
arabia
find
suggest
merscov
circul
dromedari
camel
year
saudi
arabia
total
antibodi
specif
spike
protein
requir
high
titer
neutral
merscov
rang
neutral
antibodi
titer
use
recombin
merscov
spike
protein
subunit
elisa
relisa
found
antibodi
spike
protein
optim
screen
also
determin
serum
sampl
isol
dromedari
camel
posit
test
relisa
addit
posit
sampl
test
use
establish
recombin
immunofluoresc
assay
show
sampl
antibodi
merscov
use
antimerscov
nucleocapsid
indirect
elisa
follow
month
infect
merscov
neutral
antibodi
titer
month
infect
human
serum
sampl
month
infect
howev
patient
lower
titer
neutral
antibodi
month
infect
low
titer
antibodi
patient
attribut
viral
shed
persist
site
infect
ie
mucos
site
might
attribut
neutral
effect
lead
reduct
proport
antibodi
hand
longterm
persist
antibodi
patient
might
explain
merscov
infect
induc
longliv
memori
b
cell
turn
form
antibodysecret
plasma
cell
store
bone
morrow
reexposur
viru
similar
epitop
thu
antibodi
may
protect
human
reinfect
merscov
even
though
concentr
antibodi
serum
low
thu
conclud
type
assay
use
reconsid
great
sensit
viral
detect
test
requir
identifi
conserv
protein
viru
serotyp
induc
effect
antibodymedi
immun
well
cellmedi
immun
fact
longitudin
studi
carri
dromedari
camel
unit
arab
emir
uae
demonstr
serum
sampl
collect
day
dam
parturit
high
level
specif
antimerscov
antibodi
calv
antibodi
detect
reason
result
might
camel
calv
consum
low
amount
colostrum
first
hour
low
level
igg
antibodi
dam
milk
start
declin
hour
postparturit
howev
level
specif
antimerscov
antibodi
serum
calv
increas
peak
day
postparturit
decreas
next
month
thu
neutral
activ
function
lost
calv
rest
low
antibodi
titer
result
may
explain
surviv
merscov
calv
serum
igg
antibodi
may
suffici
protect
immun
despit
potenti
neutral
antibodi
serum
antimerscov
antibodi
might
use
valuabl
indic
viral
diagnosi
thu
serum
sampl
posit
specif
antibodi
would
serv
confirm
diagnosi
merscov
infect
recombinantmodifi
vaccinia
viru
ankara
mva
express
fulllength
merscov
spike
protein
induc
highlevel
specif
neutral
antibodi
respons
vaccin
balbc
mice
via
intramuscular
im
subcutan
sc
rout
inject
sever
studi
report
im
sc
intraderm
rout
id
use
vaccin
administr
provid
good
level
protect
merscov
sarscov
infect
protect
level
may
attribut
downstream
stimul
favor
immun
respons
howev
type
vaccin
may
elicit
antibodymedi
diseas
enhanc
ade
nonneutr
epitop
encod
glycoprotein
mvamerscovsspecif
neutral
antibodi
titer
highli
detect
either
singl
immun
day
booster
immun
day
dose
plaqu
form
unit
pfu
compar
antibodi
level
previou
studi
sarscov
high
antibodi
level
effici
block
epitop
merscov
spike
protein
confirm
antibodi
specif
carri
test
serum
obtain
second
booster
sarscov
howev
serum
show
undetect
level
neutral
antibodi
sarscov
previous
correl
level
specif
neutral
antibodi
spike
protein
protect
immun
anim
infect
sarscov
shown
thu
mvamerss
vaccin
effect
stimul
humor
cellmedi
respons
addit
vaccin
effici
similar
studi
conduct
clinic
test
especi
respect
immunogen
recombin
mva
vaccin
mvamerscov
elicit
specif
cell
respons
merscov
infect
im
sc
rout
follow
primeandboost
immun
regim
specif
cell
mous
spleen
stimul
peptid
show
upregul
express
booster
vaccin
increas
level
cell
respons
anoth
studi
use
adenoviru
type
base
vaccin
express
merscov
protein
demonstr
abil
vaccin
induc
system
mucos
antigenspecif
immun
administ
via
im
intragastr
ig
rout
studi
prove
sera
vaccin
mice
high
level
antigenspecif
igg
neutral
antibodi
specif
cell
respons
detect
case
vaccin
administ
ig
rout
howev
immun
im
rout
gener
persist
antigenspecif
cell
respons
spleen
lung
vaccin
anim
protect
neutral
antibodi
cellmedi
respons
strongli
elicit
challeng
monkey
immun
adenoviralbas
sar
vaccin
express
np
protein
sarscov
addit
elicit
humor
cellmedi
respons
confirm
adenoviralbas
sarscov
vaccin
encod
rbd
hand
preexist
immun
respons
mva
adenoviru
vector
one
limit
use
viral
vectorbas
vaccin
may
caus
harm
immun
respons
inflamm
although
mvamerscov
vector
strong
induc
cellular
antibodi
respons
concern
safeti
use
vectorbas
vaccin
studi
shown
rbdbase
subunit
sarscov
vaccin
effect
safer
viral
vector
candid
report
immun
mice
rbdbase
vaccin
im
rout
induc
longterm
protect
sarscov
infect
thu
target
merscovrbd
one
strategi
vaccin
develop
immunogen
fragment
within
merscov
spike
protein
test
evalu
remark
stronger
immunogen
merscovrbd
protein
elicit
significantli
higher
titer
neutral
antibodi
vaccin
mice
antibodi
capabl
block
bind
merscovrbd
receptor
promis
trend
develop
effect
safe
merscov
vaccin
two
avail
antibodi
capabl
bind
rbd
protein
inhibit
interact
therefor
potenti
inhibitor
develop
antibodi
test
mous
model
least
effect
inhibit
merscov
replic
test
vaccin
candid
dromedari
camel
conduct
moreov
develop
human
monoclon
antibodi
mab
report
demonstr
inhibit
merscov
infect
anoth
studi
reveal
mice
rabbit
develop
high
titer
neutral
antibodi
stimul
intranas
vaccin
merscovrbdbas
subunit
vaccin
strong
potenti
induc
mucos
neutral
iga
respons
rbd
merscov
protein
rbd
fragment
shown
induc
neutral
antibodi
immun
rabbit
wherea
fragment
effect
immun
mice
result
demonstr
express
recombin
protein
rbd
vaccin
potenti
trigger
product
specif
antibodi
mice
sc
rout
two
booster
vaccin
neutral
antibodi
effect
merscov
vero
cell
vitro
pathogen
mucosaldepend
administr
vaccin
stimul
potent
mucos
iga
respons
would
better
rout
induct
increas
mucos
immun
respons
prevent
infect
merscov
report
local
system
immun
induc
effect
immun
pathway
mucos
iga
vaccin
anim
provid
crossprotect
homolog
heterolog
strain
influenza
viru
lead
longterm
protect
due
memori
respons
moreov
longterm
protect
report
sarscov
infect
rout
zhang
et
al
report
promis
result
use
protein
mous
immun
via
rout
contrast
sc
pathway
mice
immun
intranas
protein
exhibit
markedli
high
level
specif
iga
lung
howev
compar
sera
mice
treat
sc
rout
sera
mice
immun
rout
contain
slightli
higher
level
mucos
iga
hand
level
igg
mice
immun
protein
via
sc
rout
singl
dose
administ
via
rout
level
igg
rel
low
sever
dose
month
titer
igg
high
persist
long
term
data
confirm
protein
capabl
trigger
strong
local
mucos
respons
especi
rout
moreov
specif
cellmedi
immun
respons
spleen
immun
mice
gener
protein
find
indic
mucos
humor
cellular
immun
respons
might
contribut
merscov
prevent
induc
rbd
subunit
vaccin
due
abil
merscovrbdbas
vaccin
induc
effect
systemat
mucos
neutral
antibodi
subunit
might
consid
promis
potenti
candid
prevent
merscov
infect
strong
specif
igg
antibodi
respons
rbd
gener
admerss
week
postimmun
level
induc
antibodi
significantli
higher
immun
via
im
rout
immun
via
ig
rout
result
impli
recombin
viru
capabl
induc
longterm
specif
antibodi
respons
via
rout
neutral
antibodi
product
caus
coronavirus
usual
increas
immun
use
conjunct
adjuv
report
inocul
mice
merscov
spike
protein
alon
induc
suffici
antibodi
product
unless
viral
protein
bound
adjuv
caus
potent
respons
neutral
antibodi
alum
adjuv
elicit
antigenspecif
antibodi
cellularmedi
respons
might
use
merscov
subunit
vaccin
administr
howev
alum
alon
induc
potent
respons
unless
combin
anoth
adjuv
glucopyranosyl
lipid
synthet
agonist
cocktail
improv
effect
merscovrbdbas
subunit
vaccin
coleman
et
al
show
immun
respons
sarscov
merscov
nanoparticl
increas
significantli
approxim
use
adjuv
alum
respect
studi
consist
anoth
investig
term
product
antisarscov
neutral
antibodi
mice
matrix
consist
two
differ
compon
saponin
fraction
matrixa
fractionc
saponin
weaker
part
saponin
matrixc
fractionc
saponin
highli
activ
adjuv
clinic
trial
matrix
proven
potent
adjuv
anoth
studi
use
matrix
adjuv
significantli
boost
level
antibodi
titer
util
adjuv
might
enhanc
immunogen
safeti
merscov
vaccin
develop
innat
immun
respons
import
element
antivir
defens
adapt
immun
investig
requir
achiev
better
understand
innat
immun
respons
merscov
thu
suffici
data
highli
pathogen
merscov
includ
understand
mediat
innat
immun
pathway
viru
regul
pave
way
develop
effect
antivir
therapeut
vaccin
candid
provok
specif
immun
respons
without
diseas
progress
effect
vaccin
formul
date
effect
vaccin
target
specif
protein
antigen
merscov
merscov
contain
accessori
viral
protein
orf
orf
orf
addit
merscov
protein
membran
matrix
protein
structur
protein
may
import
role
develop
vaccin
candid
thu
target
viral
protein
might
facilit
vaccin
develop
limit
abil
inhibit
ifn
product
bind
dsrna
viru
addit
merscovrbdbas
vaccin
particularli
specif
residu
induc
strong
high
antibodi
titer
shown
neutral
effect
merscov
infect
immun
anim
howev
test
residu
human
cell
requir
confirm
efficaci
potenti
vaccin
thu
proteinbas
vaccin
contain
rbd
great
potenti
elicit
highli
neutral
antibodi
respons
sever
epitop
addit
merscov
target
mucosa
respiratori
tract
design
vaccin
enhanc
induct
strong
immun
via
rout
would
one
best
strategi
block
merscov
infect
sever
factor
affect
immunogen
vaccin
vaccin
appropri
rout
administr
thu
select
optim
rout
administr
proper
adjuv
specif
conserv
antigen
play
signific
role
merscov
vaccin
develop
efficaci
candid
vaccin
